FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Described is isolated human antibody or antibody fragment, which bind human delta-like ligand 4 (HDll4) in a specific way, said human antibody or antibody fragment contains heavy chain variable region (HCVR), which contains three complementarity-determining regions (CDR) of heavy chain, and light chain variable region (LCVR), which contains three CDR of light chain, where said three CDR of heavy chain contain CDR1, CDR2 and CDR3 sequences SEQ ID NO:429 or SEQ ID NO:901, and said three CDR of light chain contain CDR1, CDR2 and CDR3 sequences SEQ ID NO:437 or SEQ ID NO:903, and where said antibody or its fragment binds with epitope within N-end-DSL domain of hDll4. Described is isolated molecule of nucleic acid, coding described antibody or its antigen-binding fragment. Presented is expression vector, containing described nucleic acid molecule and system "host-vector" for obtaining described antibody. Described is composition for facilitation of course or inhibition of Dll4-mediated human disease or disorder, containing described antibody or its fragment.
EFFECT: claimed is method of obtaining described antibody against human Dll4 or its antigen-binding fragment.
25 cl, 16 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587620C2 |
METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587624C2 |
NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
ANTIBODIES OF HIGH AFFINITY TO IL-6-RECEPTOR OF HUMANS | 2007 |
|
RU2433138C2 |
HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
THERAPEUTIC METHODS OF VASCULAR EYE DISEASE TREATMENT WITH Dll4 ANTAGONISTS | 2007 |
|
RU2429876C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
Authors
Dates
2012-04-27—Published
2007-12-13—Filed